Breast Cancer Drug Futures

Additional Information

Globally, breast cancer is the second most common cancer after lung cancer....

....and the most common cancer for women. It is the second most common cause of death from cancer in women after lung cancer. The breast cancer market is a steadily growing market due to effective treatments which have decreased mortality and resulted in a longer duration of therapy. The five-year survival rates for women with breast cancer have increased from under 70% 50 years ago to around 90% now.

Approximately 47% of breast cancer sales were derived from the US, with 41% Europe and 12% in Japan. Over the next six years Espicom forecasts that novel therapies including targeted monoclonal antibodies and small-molecule inhibitors, will increasingly be used in combination with chemotherapy and hormonal therapy.

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service from Espicom, Breast Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...

Track the drug’s progress and stay in-touch with developments
Understand the drug’s novelty and mode of action
Evaluate the strength of the company developing/producing the drug
Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
Know the launch timeframe for new products or indications
Be aware of promising mid-stage development candidates
Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
Review significant clinical trial results

STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…

Novelty/rationale for mechanism of action
Current status
Proof of concept/clinical data
Development risks
Company expertise
Competition within the market-place
Sales forecast (for key late-stage and launched products)
Competitor ratio analysis score
Clinical trial results

OVER 65 CURRENT PROJECTS COVERED:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved
Anastrozole
Bevacizumab
BIIB021
Capecitabine
Docetaxel
Doxorubicin
Fulvestrant
Gemcitabine
Goserelin
Ixabepilone
Lapatinib
Letrozole
Paclitaxel
Pazopanib
Saracatinib
Tamoxifen
Tegafur+gimeracil+oteracil
Tegafur+uracil
Phase III
Erbulin
Everolimus
Pertuzumab
Ramucirumab
Trabectedin
Vadimezan
Phase II/III
Pazopanib
Phase II
AE37
Axitinib
Bavituximab
Cixutumumab
E75 GM-CSF adjuvant vaccine
Figitumumab
Gimatecan
Linifanib
Motesanib diphosphate
NOV-002
Olaparib
Pemetrexed disodium
Retaspimycin
Sorafenib
SU14813
TSU-68
YM155
Phase I/II
AUY922
BIIB021
IMP321
MVA-BN-HER2
Tivozanib
Phase I
Adecatumumab
Brivanib
PTC299
Withdrawn
Saracatinib
Sagopilone
Sunitinib malate
Development Discontinued
ABT-751

CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom’s Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!
4D Research is Espicom’s tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom’s leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.